Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.01 -	0.06 930.39%	6.05 9,345.85%	1.68 72.19%	0.64 62.23%	0.18 72.19%
company equity multiplier	-0.05 -	-0.06 22.18%	1.05 1,744.63%	1.09 3.50%	1.14 5.00%	1.09 4.22%
days of inventory outstanding
days of payables outstanding
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1.08 -	1.14 5.38%	1.03 8.93%	1.02 1.32%	0.99 2.54%	0.97 2.23%
effective tax rate	-0.07 -	-0.12 65.79%			0.01 -
enterprise value multiple	-41.15 -	-38.59 6.22%	-0.72 98.13%	-1.83 154.21%	0.36 119.60%	-1.37 482.75%
fixed asset turnover
free cash flow per share	-0.25 -	-0.43 74.94%	-0.79 82.61%	-1.88 138.26%	-1.04 45.00%	-0.26 74.96%
gross profit margin
interest coverage	-12.90 -	-7.38 42.76%	-26.04 252.78%	-2.76K 10,489.48%	182.52 106.62%
inventory turnover
long term debt to capitalization		-2.79 -
net income per ebt	1 -	1.12 11.93%	1 10.66%	1 0%	0.99 0.55%	1 0.55%
net profit margin
operating cash flow per share	-0.25 -	-0.43 74.94%	-0.79 82.61%	-1.88 138.26%	-1.04 45.00%	-0.26 74.96%
operating profit margin
payables turnover
pretax profit margin
price fair value	-64.07 -	-16.34 74.50%	1.24 107.56%	2.94 137.97%	0.36 87.87%	2.84 695.34%
receivables turnover
return on assets	-32.06 -	-8.76 72.66%	-0.33 96.25%	-1.01 207.73%	-1.46 43.85%	-1.27 12.63%
return on capital employed	1.56 -	1.67 7.27%	-0.33 120.02%	-1.08 222.77%	-1.68 55.84%	-1.43 14.88%
return on equity	1.68 -	0.56 66.59%	-0.35 161.69%	-1.10 218.50%	-1.66 51.05%	-1.39 16.32%
total debt to capitalization		-2.79 -

NASDAQ:VIRI

Virios Therapeutics, Inc.

Last Close

0.39

17/05 20:00

Market Cap

7.90M

Beta: 1.93

Volume Today

258.46K

Avg: 2.87M

PE Ratio

−1.08

PFCF: −1.11